| 1 |
尤寿江, 曹勇军, 章春园, 等. 成人烟雾病的临床特点、分期及代偿机制分析[J/OL]. 中华脑血管病杂志(电子版), 2011, 5(2): 89-95.
|
| 2 |
Ihara M, Yamamoto Y, Hattori Y, et al. Moyamoya disease: diagnosis and interventions[J]. Lancet Neurol, 2022, 21(8): 747-758.
|
| 3 |
Suzuki J, Takaku A. Cerebrovascular "Moyamoya" disease: disease showing abnormal net-like vessels in base of brain[J]. Arch Neurol, 1969, 20(3): 288-299.
|
| 4 |
Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome[J]. N Engl J Med, 2009, 360(12): 1226-1237.
|
| 5 |
中华医学会神经外科学分会. 烟雾病和烟雾综合征诊断与治疗中国专家共识(2024版)[J]. 中华神经外科杂志, 2024, 40(3): 220-229.
|
| 6 |
Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives[J]. Lancet Neurol, 2008, 7(11): 1056-1066.
|
| 7 |
刘阳, 郭高超, 赵黎明, 等. 儿童烟雾病的临床特征、手术治疗及疗效分析[J/OL]. 中华脑血管病杂志(电子版), 2021, 15(4): 237-241.
|
| 8 |
Pang CH, Cho WS, Kang HS, et al. Benefits and risks of antiplatelet medication in hemodynamically stable adult Moyamoya disease[J]. Sci Rep, 2021, 11(1): 19367.
|
| 9 |
Lu J, Li Z, Zhao Y, et al. Hemorrhagic transformation in ischemic Moyamoya disease: clinical characteristics, radiological features, and outcomes[J]. Front Neurol, 2020, 11: 517.
|
| 10 |
Yan Y, Li Y, Huang L, et al. A comprehensive Meta-analysis for bypass surgery in adult Moyamoya[J]. World Neurosurg, 2019, 124: 161-170.
|
| 11 |
Bang OY, Fujimura M. Medical management of adult Moyamoya disease: a review and relevant cases with ischemic events[J]. J Stroke, 2025, 27(1): 1-18.
|
| 12 |
Fujimura M, Tominaga T, Kuroda S, et al. 2021 Japanese guidelines for the management of Moyamoya disease: guidelines from the Research Committee on Moyamoya disease and Japan Stroke Society[J]. Neurol Med Chir (Tokyo), 2022, 62(4): 165-170.
|
| 13 |
Liu H, Fukasawa T, Anno T, et al. Incidence, prevalence, and treatment of Moyamoya disease in Japan: a population-based descriptive study[J]. J Stroke Cerebrovasc Dis, 2024, 33(8): 107770.
|
| 14 |
Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China: its clinical features and outcomes[J]. Stroke, 2012, 43(1): 56-60.
|
| 15 |
高坤, 杨波, 李红伟, 等. 河南地区烟雾病临床特征及治疗分析[J]. 河南医学研究, 2018, 27(5): 788-792.
|
| 16 |
李治, 吕梁, 黄莹, 等. 回顾性分析云南地区烟雾病流行病学特点[J]. 世界最新医学信息文摘, 2019,19(94): 18-19, 21.
|
| 17 |
Oki K, Katsumata M, Izawa Y, et al. Trends of antiplatelet therapy for the management of Moyamoya disease in Japan: results of a nationwide survey[J]. J Stroke Cerebrovasc Dis, 2018, 27(12): 3605-3612.
|
| 18 |
Kraemer M, Berlit P, Diesner F, et al. What is the expert's option on antiplatelet therapy in Moyamoya disease? Results of a worldwide survey[J]. Eur J Neurol, 2012, 19(1): 163-167.
|
| 19 |
Shulman JG, Snider S, Vaitkevicius H, et al. Direct visualization of arterial emboli in Moyamoya syndrome[J]. Front Neurol, 2017, 8: 425.
|
| 20 |
Yamashita M, Oka K, Tanaka K. Cervico-cephalic arterial thrombi and thromboemboli in Moyamoya disease--possible correlation with progressive intimal thickening in the intracranial major arteries[J]. Stroke, 1984, 15(2): 264-270.
|
| 21 |
Kim DY, Son JP, Yeon JY, et al. Infarct pattern and collateral status in adult Moyamoya disease[J]. Stroke, 2017, 48(1): 111-116.
|
| 22 |
Chen J, Duan L, Xu W H, et al. Microembolic signals predict cerebral ischaemic events in patients with Moyamoya disease[J]. Eur J Neurol, 2014, 21(5): 785-790.
|
| 23 |
Pompsch M, Veltkamp R, Diehl RR, et al. Microembolic signals and antiplatelet therapy in Moyamoya angiopathy[J]. J Neurol, 2022, 269(12): 6605-6612.
|
| 24 |
Kuroda S, Hashimoto N, Yoshimoto T, et al. Radiological findings, clinical course, and outcome in asymptomatic Moyamoya disease[J]. Stroke, 2007, 38(5): 1430-1435.
|
| 25 |
Chen J, Hu YH, Gao S, et al. Accidental microembolic signals: prevalence and clinical relevance[J]. Neurovasc Imaging, 2016, 2(1): 5.
|
| 26 |
Kuroda S, Yamamoto S, Funaki T, et al. Five-Year stroke risk and its predictors in asymptomatic Moyamoya disease: Asymptomatic Moyamoya Registry (AMORE)[J]. Stroke, 2023, 54(6): 1494-1504.
|
| 27 |
Acker G, Lange C, Schatka I, et al. Brain perfusion imaging under acetazolamide challenge for detection of impaired cerebrovascular reserve capacity: positive findings with 15O-water PET in patients with negative 99mTc-HMPAO SPECT findings[J]. J Nucl Med, 2018, 59(2): 294-298.
|
| 28 |
Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369(1): 11-19.
|
| 29 |
Bersano A, Khan N, Fuentes B, et al. European Stroke Organisation (ESO) guidelines on Moyamoya angiopathy endorsed by Vascular European Reference Network (VASCERN)[J]. Eur Stroke J, 2023, 8(1): 55-84.
|
| 30 |
Seo WK, Kim JY, Choi EH, et al. Association of antiplatelet therapy, including cilostazol, with improved survival in patients with Moyamoya disease in a nationwide study[J]. J Am Heart Assoc, 2021, 10(5): e017701.
|
| 31 |
Luo Y, Cao Z, Ye H, et al. Antiplatelet therapy may improve the prognosis of patients with Moyamoya disease: a 12-year retrospective study[J]. J Neurol, 2023, 270(8): 3876-3884.
|
| 32 |
Onozuka D, Hagihara A, Nishimura K, et al. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic Moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)[J]. BMJ Open, 2016, 6(3): e009942.
|
| 33 |
Ye F, Li J, Wang T, et al. Efficacy and safety of antiplatelet agents for adult patients with ischemic Moyamoya disease[J]. Front Neurol, 2020, 11: 608000.
|
| 34 |
Chiba T, Setta K, Shimada Y, et al. Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic Moyamoya disease: subanalysis of a prospective cohort[J]. J Stroke Cerebrovasc Dis, 2018, 27(11): 3373-3379.
|
| 35 |
Lu M, Zhang H, Liu S, et al. Effects of antiplatelet therapy on reducing stroke risk in patients with Moyamoya disease: the role of postcontrast MR vessel wall imaging[J]. Eur Radiol, 2025, 35(10): 5911-5921.
|
| 36 |
Liu T, Qin M, Xiong X, et al. Benefits and risks of antiplatelet therapy for Moyamoya disease: a systematic review and Meta-analysis[J]. Front Neurol, 2023, 14: 1132339.
|
| 37 |
Rashad S, Saqr KM, Fujimura M, et al. The hemodynamic complexities underlying transient ischemic attacks in early-stage Moyamoya disease: an exploratory CFD study[J]. Sci Rep, 2020, 10(1): 3700.
|
| 38 |
Yamada S, Oki K, Itoh Y, et al. Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on Moyamoya disease in Japan[J]. J Stroke Cerebrovasc Dis, 2016, 25(2): 340-349.
|
| 39 |
Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic Moyamoya disease[J]. Stroke, 2014, 45(5): 1415-1421.
|
| 40 |
Haller S, Vernooij MW, Kuijer JPA, et al. Cerebral microbleeds: imaging and clinical significance[J]. Radiology, 2018, 287(1): 11-28.
|
| 41 |
Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of Moyamoya disease (spontaneous occlusion of the circle of Willis)[J]. Neurol Med Chir (Tokyo), 2012, 52(5): 245-266.
|
| 42 |
Bagyinszky E, Yang Y, An SSA. Multisystemic impact of RNF213 Arg4810Lys: a comprehensive review of Moyamoya disease and associated vasculopathies[J]. Int J Mol Sci, 2025, 26(16): 7864.
|
| 43 |
Soman T, Rafay MF, Hune S, et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke[J]. Stroke, 2006, 37(4): 1120-1122.
|
| 44 |
Aihara Y, Kashiwase S, Chiba K, et al. Aspirin use and platelet aggregation in ischemic onset-type pediatric Moyamoya patients with intractable headaches (moya-ache)[J]. Childs Nerv Syst, 2021, 37(5): 1649-1657.
|
| 45 |
Funaki T, Takahashi JC, Houkin K, et al. High rebleeding risk associated with choroidal collateral vessels in hemorrhagic Moyamoya disease: analysis of a nonsurgical cohort in the Japan adult Moyamoya trial[J]. J Neurosurg, 2019, 130(2): 525-530.
|
| 46 |
Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in Moyamoya disease[J]. Stroke, 1983, 14(1): 50-58.
|
| 47 |
Ryu J, Lee KM, Woo HG, et al. Morphologic differences between ruptured and unruptured choroidal anastomosis in adult Moyamoya disease: a high-resolution vessel wall imaging study[J]. J Neurosurg, 2024, 140(2): 441-449.
|
| 48 |
Xiang Y, Zhang P, Zhao P, et al. Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization[J]. Front Pharmacol, 2022, 13: 841174.
|
| 49 |
Zhao Y, Zhang Q, Zhang D, et al. Effect of aspirin in postoperative management of adult ischemic Moyamoya disease[J]. World Neurosurg, 2017, 105: 728-731.
|
| 50 |
Abedi A, Sizdahkhani S, Choi W, et al. Cilostazol for the management of Moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions[J]. Neurosurg Focus, 2023, 55(4): E9.
|
| 51 |
Michelson AD. Platelets[M]. 2nd ed. Burlington (Canada): Academic Press, 2007: 1181-1191.
|
| 52 |
Ando S, Tsutsui S, Miyoshi K, et al. Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic Moyamoya disease: subanalysis of a prospective cohort[J]. Neurol Res, 2019, 41(5): 480-487.
|
| 53 |
Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial[J]. Lancet Neurol, 2010, 9(10): 959-968.
|
| 54 |
Hartkamp NS, Hendrikse J, de Borst GJ, et al. Intracerebral steal phenomenon in symptomatic carotid artery disease[J]. J Neuroradiol, 2019, 46(3): 173-178.
|